Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AnGes Takes DNA Vaccine Tack As It Enters Virus R&D Fray

Japan Venture Joins Others In Same Approach

Executive Summary

Japanese bioventure goes down the DNA vaccine route, along with several others worldwide, pointing to potential development speed and safety advantages.

You may also be interested in...



White House Hypes Chloroquine, A Drug Currently In Shortage, As Coronavirus Treatment Hope

Efficacy trials are under way and one supplier already has said it would restart production to meet the anticipated demand.

Coronavirus Hasn’t Sparked CURE ID Physician Social Network Interest

US FDA/NIH smartphone app is intended to allow clinicians and others to talk about potential treatments for infectious diseases, but so far COVID-19-related activity has been limited.

Takeda Kicks Off Effort On Globulin, Other COVID-19 Therapies

Japan's largest pharma firm has joined the global fray to develop potential therapies for the spreading coronavirus outbreak, focusing initially on its plasma products expertise. But this approach has had some challenges in China.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141841

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel